ABL Diagnostics specializes in the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases (AIDS, viral hepatitis and tuberculosis) by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. Export accounts for 69.7% of net sales.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
14/09/26	€2.420	-3.97%	6,018
11/09/26	€2.520	+5.00%	18,211
10/09/26	€2.400	-6.98%	5,799
09/09/26	€2.580	+5.74%	26,733
08/09/26	€2.440	+0.83%	54

Real-time Euronext Paris

More quotes

Annual profits - Rate of surprise

Company calendar

Real-time Euronext Paris 20:12:19 14/09/2026 HKT			5-day change	1st Jan Change
2.420 ^EUR	-3.97%		0.00%	-19.33%

09-11	ABL Diagnostics Société anonyme proposed to acquire Business operations and assets of IntegraGen SA.	CI
09-11	ABL Diagnostics Offers to Acquire IntegraGen Amid Reorganization Proceedings	MT

Market Cap	40.49M 47M 38.34M 34.75M 65.2M 4.49B 65.53M 455M 175M 2.28B 177M 173M 7.22B	P/E 2024	123x	P/E 2025	50x
Enterprise Value	41.43M 48.08M 39.23M 35.55M 66.7M 4.59B 67.04M 466M 179M 2.34B 181M 177M 7.38B	EV / Sales 2024	7,098,474x	EV / Sales 2025	6,185,843x
Free-Float	6.2%	Yield 2024	2.03%	Yield 2025	3.67%

Markets		Quality
Euronext Paris	ABLD	Real-time
Börse Stuttgart	9BK0	Delayed
CBOE	0OPO	Real-time
CBOE	FAUVp	Real-time
Deutsche Boerse AG	9BK0	Delayed

09-11	ABL Diagnostics Société anonyme proposed to acquire Business operations and assets of IntegraGen SA.	CI
09-11	ABL Diagnostics Offers to Acquire IntegraGen Amid Reorganization Proceedings	MT
09-11	Abionyx Pharma Partners With ABL Diagnostics Division for Viral Safety Testing of CER-001	MT
09-11	Abionyx Pharma Enters into Strategic Partnership with TEXCELL (Abl Diagnostics) for Viral Safety and Clearance of Biologics	CI
09-11	ABL Diagnostics partners with Abionyx Pharma
09-09	ABL Diagnostics Maintains Revenue Guidance for the Financial Year 2026	CI
09-09	ABL Diagnostics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-10	ABL Diagnostics Plans Listing Transfer to Euronext Growth Paris	MT
07-23	French Court OKs ABL Diagnostics' Industrial Plan to Acquire Texcell	MT
07-23	ABL Diagnostics Société anonyme agreed to acquire Assets and Business Operations from Texcell SA for ?0.78 million.	CI
07-03	Abl Diagnostics Société Anonyme Approves Dividend Distribution for Fiscal Year 2025, Payable on July 7, 2026	CI
06-12	Abl Diagnostics Sa and Cdl Pharma Secure Multi-Year International Contract of Up to Eur 2.7 Million Through 2031	CI
06-12	ABL Diagnostics Signs Multi-year Contract to Provide Clinical Trial Services	MT

ABL Diagnostics Stock

Stocks

ABLD

FR001400AHX6

Medical Equipment, Supplies & Distribution

Valuation: ABL Diagnostics

Chart: ABL Diagnostics

Latest news: ABL Diagnostics

Press Releases: ABL Diagnostics

News in other languages: ABL Diagnostics

Quotes and Performance

Price Extremes

Managers and Directors: ABL Diagnostics

Latest insider transactions

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

09-11	ABL Diagnostics (ABLD) Announces the Filing of a Takeover Bid for Integragen	BU
09-11	ABL Diagnostics - TEXCELL Strengthens Its Position as an International Reference in Safety and Viral Clearance With a New Strategic Partnership With ABIONYX Pharma	BU
09-09	ABL Diagnostics Confirms Its Change of Scale in the First Half of 2026: Revenue up 90.0%, EBITDA Multiplied by More Than Four and Net Income up 343.3% Compared to the First Half of 2025	BU
08-28	ABL Diagnostics: Ordinary and Extraordinary General Meeting of September 17, 2026 – Arrangements for the Availability and Consultation of Preparatory Documents	BU
08-08	ABL Diagnostics - Proposed Transfer of the Listing of Its Securities From the Regulated Market of Euronext Paris to Euronext Growth Paris	BU

01:10pm	Deux offres de reprise déposées pour IntegraGen
09-11	ABL Diagnostics (ABLD) annonce le dépôt d’une offre de reprise de IntegraGen
09-11	Bourse : Alstom et Airbus engrangent de gros contrats, Oracle rassure
09-11	ABL Diagnostics s'associe à Abionyx Pharma
09-11	ABL DIAGNOSTICS - TEXCELL RENFORCE SA POSITION DE RÉFÉRENCE INTERNATIONALE EN SÉCURITÉ ET CLAIRANCE VIRALE AVEC UN NOUVEAU PARTENARIAT STRATÉGIQUE AVEC ABIONYX PHARMA

1 day	-3.97%
Current month	-0.82%
1 month	-0.82%
3 months	-3.97%
6 months	-27.11%
Current year	-19.33%

1 week	2.4	2.78
1 month	2.2	2.78
Current year	2.12	5
1 year	2.12	5
3 years	2.12	9.7
5 years	1.99	26
10 years	1.28	26

Director	Title	Age	Since
Laure Raffaelli BRD	Director/Board Member	-	-
Noemie Sadoun CHM	Chairman	-	-
Deborah Szafir BRD	Director/Board Member	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
28/7/26	Advanced Biological Laboratories SA	Sell	Company	-60,000	0.3723%
20/7/26	Advanced Biological Laboratories SA	Sell	Company	-65,616	0.4072%
6/7/26	Advanced Biological Laboratories SA	Sell	Company	-62,308	0.3867%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABL DIAGNOSTICS	-3.97%	0.00%	-50.61%	-75.05%	47M
ABBOTT LABORATORIES	+1.34%	-1.87%	-21.16%	+0.87%	176B
MEDTRONIC PLC	+2.31%	+0.74%	-0.39%	+13.56%	116B
CENCORA, INC.	+0.78%	-0.16%	+11.25%	+83.16%	61.36B
HOYA CORPORATION	-1.15%	-7.08%	+5.83%	+39.93%	49.42B
BECTON, DICKINSON AND COMPANY	+1.45%	+0.63%	-2.97%	-31.89%	48.44B
DEXCOM, INC.	+1.61%	0.00%	+11.84%	-16.76%	31.33B
MEDLINE INC.	-0.31%	-6.33%	-	-	28.54B
WEST PHARMACEUTICAL SERVICES, INC.	+0.62%	+2.91%	+34.96%	-12.65%	24.37B
TERUMO CORPORATION	+0.73%	-6.97%	-12.66%	+4.70%	21.57B
Average	+0.36%	-4.02%	-2.66%	+0.65%	55.78B
Weighted average by Cap.	+1.17%	-4.84%	-3.77%	+12.33%

	2024	2025
Net sales	5.87 6.81 5.56 5.04 9.45 650.81 9.5 66.01 25.38 331.1 25.58 25.02 1.05K	7.97 9.25 7.54 6.84 12.83 883.24 12.89 89.58 34.45 449.36 34.72 33.96 1.42K
Net income	285K 331K 270K 245K 459K 31.62M 461K 3.21M 1.23M 16.09M 1.24M 1.22M 50.83M	987K 1.15M 934K 847K 1.59M 109M 1.6M 11.1M 4.27M 55.66M 4.3M 4.21M 176M
Net Debt	2.02M 2.35M 1.92M 1.74M 3.26M 224M 3.28M 22.76M 8.75M 114M 8.82M 8.63M 361M	933K 1.08M 883K 800K 1.5M 103M 1.51M 10.49M 4.03M 52.61M 4.07M 3.98M 166M